Toth Financial Advisory’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.89M Buy
32,530
+2,769
+9% +$543K 0.67% 57
2026
Q1
$5.83M Buy
29,761
+209
+0.7% +$40.6K 0.64% 63
2025
Q4
$5.13M Buy
29,552
+2,731
+10% +$497K 0.56% 65
2025
Q3
$5.11M Buy
26,821
+624
+2% +$111K 0.55% 63
2025
Q2
$4.71M Buy
26,197
+3,828
+17% +$665K 0.55% 65
2025
Q1
$3.78M Buy
22,369
+1,050
+5% +$172K 0.46% 74
2024
Q4
$3.22M Buy
21,319
+749
+4% +$116K 0.38% 84
2024
Q3
$3.19M Buy
20,570
+212
+1% +$31.7K 0.38% 88
2024
Q2
$2.79M Buy
20,358
+1,162
+6% +$159K 0.35% 90
2024
Q1
$2.56M Buy
19,196
+402
+2% +$52.2K 0.32% 93
2023
Q4
$2.59M Sell
18,794
-17
-0.1% -$2.23K 0.35% 84
2023
Q3
$2.29M Sell
18,811
-3,287
-15% -$438K 0.35% 82
2023
Q2
$3.11M Sell
22,098
-7,606
-26% -$1.05M 0.45% 74
2023
Q1
$4.2M Sell
29,704
-9,841
-25% -$1.41M 0.66% 57
2022
Q4
$6.19M Sell
39,545
-8,060
-17% -$1.16M 1% 37
2022
Q3
$5.84M Sell
47,605
-1,712
-3% -$225K 1.06% 33
2022
Q2
$6.56M Sell
49,317
-892
-2% -$122K 1.14% 28
2022
Q1
$6.87M Sell
50,209
-108
-0.2% -$15.1K 1.03% 34
2021
Q4
$8.71M Sell
50,317
-1,466
-3% -$223K 1.19% 27
2021
Q3
$7.53M Sell
51,783
-570
-1% -$83.4K 1.14% 28
2021
Q2
$6.91M Buy
52,353
+149
+0.3% +$19.5K 1.06% 30
2021
Q1
$6.7M Sell
52,204
-1,811
-3% -$223K 1.07% 28
2020
Q4
$6.44M Buy
54,015
+985
+2% +$120K 1.1% 28
2020
Q3
$6.07M Buy
53,030
+3,735
+8% +$441K 1.17% 28
2020
Q2
$5.62M Buy
49,295
+1,739
+4% +$184K 1.22% 30
2020
Q1
$3.82M Buy
47,556
+1,745
+4% +$181K 1.1% 34
2019
Q4
$4.89M Buy
45,811
+1,728
+4% +$180K 0.99% 39
2019
Q3
$4.72M Buy
44,083
+2,631
+6% +$270K 1.03% 41
2019
Q2
$4.22M Buy
41,452
+414
+1% +$39.8K 0.94% 40
2019
Q1
$3.69M Sell
41,038
-8,740
-18% -$757K 0.86% 47
2018
Q4
$4.14M Sell
49,778
-7,176
-13% -$673K 1.13% 35
2018
Q3
$6.15M Sell
56,954
-403
-0.7% -$44.2K 1.36% 26
2018
Q2
$6.31M Buy
57,357
+2,632
+5% +$274K 1.48% 19
2018
Q1
$5.49M Sell
54,725
-540
-1% -$55.3K 1.33% 26
2017
Q4
$5.44M Sell
55,265
-1,386
-2% -$131K 1.29% 27
2017
Q3
$5.3M Sell
56,651
-3,187
-5% -$338K 1.34% 27
2017
Q2
$6.65M Sell
59,838
-4,977
-8% -$526K 1.74% 17
2017
Q1
$6.36M Sell
64,815
-3,149
-5% -$300K 1.69% 18
2016
Q4
$6.25M Buy
67,964
+420
+0.6% +$36.2K 1.79% 15
2016
Q3
$5.72M Sell
67,544
-97
-0.1% -$8.15K 1.68% 19
2016
Q2
$5.51M Buy
67,641
+1,710
+3% +$130K 1.68% 19
2016
Q1
$4.71M Buy
65,931
+2,258
+4% +$151K 1.54% 25
2015
Q4
$4.53M Buy
63,673
+654
+1% +$44K 1.5% 29
2015
Q3
$3.87M Buy
63,019
+1,787
+3% +$125K 1.42% 32
2015
Q2
$4.44M Buy
61,232
+3,983
+7% +$294K 1.48% 29
2015
Q1
$4.4M Buy
57,249
+9,891
+21% +$708K 1.48% 29
2014
Q4
$3.18M Buy
47,358
+10,590
+29% +$668K 1.1% 40
2014
Q3
$2.23M Buy
36,768
+6,148
+20% +$379K 0.84% 46
2014
Q2
$1.8M Buy
30,620
+2,689
+10% +$157K 0.68% 53
2014
Q1
$1.62M Sell
27,931
-694
-2% -$37.2K 0.66% 53
2013
Q4
$1.53M Sell
28,625
-7,073
-20% -$420K 0.65% 53
2013
Q3
$2.21M Buy
35,698
+9,491
+36% +$568K 1.03% 43
2013
Q2
$1.59M Buy
+26,207
New +$1.56M 0.78% 49

Other funds holding DGX

Toth Financial Advisory's DGX Position: Q2 2026 in Review

Toth Financial Advisory increased its Quest Diagnostics (DGX) stake by 9.3% in Q2 2026, buying an estimated $543K and bringing the position to 32,530 shares worth $6.89M. The position accounts for 0.67% of the portfolio, ranked #57.

Toth Financial Advisory first reported a position in DGX in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.71M in Q4 2021. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Toth Financial Advisory held 32,530 shares of Quest Diagnostics worth $6.89M as of Q2 2026.
  • Toth Financial Advisory bought 2,769 Quest Diagnostics shares in Q2 2026, an estimated $543K.
  • Quest Diagnostics made up 0.67% of Toth Financial Advisory's portfolio in Q2 2026, its #57 holding.
  • Toth Financial Advisory first reported a position in Quest Diagnostics in Q2 2013 and has held it in 53 quarters since.
  • Toth Financial Advisory's Quest Diagnostics position peaked at $8.71M in Q4 2021.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Toth Financial Advisory's 13F filing for Q2 2026, filed 14 Jul 2026.